Akorn, Inc. (AKRX) Announces Completion of Kilitch Drugs India Limited Acquisition
Tweet
Share
E-mailGet Alerts AKRX Hot Sheet
Join SI Premium – FREE
Akorn, Inc. (NASDAQ: AKRX) announced today that its wholly owned subsidiary, Akorn India Private Limited (“AIPL”), has completed and closed the previously announced acquisition of certain assets of Kilitch Drugs India Limited (“KDIL”), a leading contract manufacturer of sterile injectables in India, as well as certain assets of NBZ Pharma Limited.
Raj Rai, Chief Executive Officer commented, “We look forward in establishing our global presence with this acquisition as well as expanding our capabilities in becoming a world class sterile injectables manufacturer. We also look forward in working closely with the Promoters of KDIL to provide a smooth transition in the coming months.”
Raj Rai, Chief Executive Officer commented, “We look forward in establishing our global presence with this acquisition as well as expanding our capabilities in becoming a world class sterile injectables manufacturer. We also look forward in working closely with the Promoters of KDIL to provide a smooth transition in the coming months.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Holcim said to acquire part of James Hardie's EU business
- Magna Holdings makes unsolicited bid for 31% of Yatra Online
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
